Drug Name:
BLOXIVERZ Rx
Generic Name and Formulations:
Neostigmine methylsulfate 0.5mg/mL, 1mg/mL; soln for IV inj; latex-free.
Company:
Eclat Pharmaceuticals
Therapeutic Use:
Indications for BLOXIVERZ:
To reverse effects of non-depolarizing neuromuscular blocking agents (NMBAs) post-op.
Adults and Children:
See full labeling. Peripheral nerve stimulator and monitoring for twitch responses should be used to determine time of Bloxiverz initiation and the need for additional doses. Individualize. Give by IV inj slowly over a period of at least 1 min. Administer an anticholinergic (eg, atropine sulfate, glycopyrrolate) prior to (if bradycardia present) or concomitantly with Bloxiverz. Reversal of NMBAs with shorter half-lives (eg, rocuronium), or when first twitch response is substantially >10% of baseline or when a second twitch is present: 0.03mg/kg. Reversal of NMBAs with longer half-lives (eg, vecuronium, pancuronium) or when first twitch response is not substantially >10% of baseline or if rapid recovery required: 0.07mg/kg. Max total dose: 0.07mg/kg or up to a total of 5mg, whichever is less.
Contraindications:
Peritonitis. Mechanical obstruction of the intestinal or urinary tract.
Warnings/Precautions:
Should be administered by trained healthcare providers. Have treatment for anaphylaxis readily available. Maintain ventilation and patent airway. Increased risk of BP and HR complications with cardiovascular conditions (eg, coronary artery disease, cardiac arrhythmias, recent acute coronary syndrome) or myasthenia gravis. Neuromuscular dysfunction with large doses; reduce dose if recovery is nearly complete. Differentiate between myasthenic or cholinergic crisis. Renal or hepatic impairment; monitor closely. Elderly (monitor for longer periods). Labor & delivery: may induce premature labor. Pregnancy. Nursing mothers.
Pharmacological Class:
Cholinesterase inhibitor.
Interactions:
Caution with other drugs that may alter activity of metabolizing enzymes or transporters.
Adverse Reactions:
Bradycardia, nausea, vomiting, dry mouth, hypotension, dizziness, headache, insomnia, dyspnea, pruritus; hypersensitivity reactions.
Generic Availability:
YES
How Supplied:
Multi-dose vials (10mL)—10
Neurology Advisor Articles
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- Loss of Function Variants in LRRK1 and LRRK2 Not Linked to Parkinson Disease
- Smoking Promotes Disease Progression in Multiple Sclerosis
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- ZTlido Patch for Post-Shingles Pain Launching Soon
- Managing Complications of Intrathecal Baclofen Therapy
- Deep Brain Stimulation Reduces Tremor Symptoms in Parkinson Disease
- FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid
- Prevalence of Autoimmune Encephalitis in Herpes Simplex Encephalitis Explored